CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding CytomX Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 70 | +2 |
| Shares | 51.2M | 33.1K | 46.7M | −4.44M (−8.7%) |
| Value | $60.4M | $39.1K | $48.1M | −$12.3M (−20.3%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held CytomX Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 2,650,000 | $2.73M | 0.01% |
| Monimus Capital Management, LP | 364,306 | $375.2K | 0.35% |
| Aspire Growth Partners LLC | 40,780 | $42.0K | 0.04% |
| Gsa Capital Partners LLP | 38,885 | $40.0K | 0.00% |
| JustInvest LLC | 36,992 | $38.1K | 0.00% |
| Velan Capital Investment Management LP | 35,000 | $36.0K | 0.03% |
| Algert Global LLC | 33,570 | $34.6K | 0.00% |
| Traphagen Investment Advisors LLC | 30,500 | $31.4K | 0.00% |
| Miller Financial Services LLC | 25,000 | $25.8K | 0.02% |
| SBI Securities Co., Ltd. | 1,107 | $1.14K | 0.00% |
| Bell Investment Advisors, Inc | 388 | $400 | 0.00% |
| Simplex Trading, LLC | 507 | $0 | 0.00% |
Sold out (10)
Institutions that held CytomX Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Janus Henderson Group PLC | 4,809,518 | $5.70M |
| Adage Capital Partners GP, L.L.C. | 3,000,000 | $3.54M |
| Woodline Partners LP | 393,832 | $464.7K |
| Creative Planning | 107,000 | $126.3K |
| Stifel Financial Corp | 46,100 | $54.4K |
| Cornercap Investment Counsel Inc | 41,458 | $48.9K |
| Invesco Ltd. | 37,464 | $44.2K |
| Goldman Sachs Group Inc | 12,000 | $14.2K |
| EP Wealth Advisors, LLC | 10,432 | $12.3K |
| Federated Hermes, Inc. | 117 | $138 |
Not filed for Q4 2024 yet (1)
Institutions that held CytomX Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| AJOVista, LLC | 33,121 | $39.1K |